Document is current
Any future updates will be listed below
-
Authors
Riedl, Katharina A. https://orcid.org/0000-0001-5956-0051
Di Carluccio, Eleonora
Huellebrand, Markus
Hennemuth, Anja
Frye, Maike
Kaufmann, Paula
Hazizi, Mariam
Cavus, Ersin
Albrecht, Jan N.
Tahir, Enver
Erley, Jennifer
Sinn, Martin
Schoennagel, Bjoern P.
Adam, Gerhard
Kirchhof, Paulus
Blankenberg, Stefan
Lund, Gunnar
Ziegler, Andreas
Muellerleile, Kai
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 7 October 2025
Accepted: 27 January 2026
First Online: 9 February 2026
Declarations
:
: PK received research support for basic, translational, and clinical research projects from the European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last 5 years. PK is listed as inventor on two issued patents held by the University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). AZ is listed as co-inventor of an international patent on the use of a computing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1) and is scientific director and CEO of Cardio-CARE, a program by the Kühne Foundation and shareholder of the ART-EMIS Hamburg GmbH. BPS is co-founder and stakeholder of northh Medical GmbH. All other authors declare no conflicts of interest.
